Compare MED & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MED | IXHL |
|---|---|---|
| Founded | 1980 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 134.7M |
| IPO Year | N/A | N/A |
| Metric | MED | IXHL |
|---|---|---|
| Price | $11.36 | $0.29 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | 224.0K | ★ 7.8M |
| Earning Date | 02-17-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $429,695,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $470.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.10 | $0.08 |
| 52 Week High | $16.66 | $2.24 |
| Indicator | MED | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 27.26 |
| Support Level | $10.81 | $0.25 |
| Resistance Level | $11.31 | $0.34 |
| Average True Range (ATR) | 0.43 | 0.02 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 0.75 | 10.06 |
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.